Oxford Immunotec (OXFD) Tops Q3 EPS by 15c, Raises Revenue Outlook

Oxford Immunotec (NASDAQ: OXFD) reported Q3 EPS of ($0.18), $0.15 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $24.79 million.

GUIDANCE:

Oxford Immunotec sees FY2016 revenue of $85-85.8 million, versus prior guidance of $82.5-84.5 million and the consensus of $83.7 million.

For earnings history and earnings-related data on Oxford Immunotec (OXFD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c